Abstracts tagged "interleukins (IL)"

Abstract Number: 1171 • 2015 ACR/ARHP Annual Meeting
Plasma Soluble ST2 Levels Are Independently Associated with Both Carotid Atherosclerosis and Compromised Cortical Volumetric Bone Mineral Density and Microstructure in Patients with Psoriatic Arthritis
Jiayun Shen¹, Qing Shang¹, Edmund Li¹, Tracy Y. Zhu², Ling Qin² and Lai-Shan Tam¹, ¹Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, China, ²Department of Orthopaedics & Traumatology, The Chinese University of Hong Kong, Hong Kong, China
Background/Purpose: Patients with PsA have both increased risk of subclinical atherosclerosis and lower cortical volumetric BMD (vBMD) compared with the general population, probably as a…
Abstract Number: 1677 • 2015 ACR/ARHP Annual Meeting
Disease-Regulated Expression of Anti-Inflammatory Interleukin-10 for the Treatment of Rheumatoid Arthritis
Mathijs G.A. Broeren¹, Miranda B. Bennink¹, Onno J. Arntz², Wim van den Berg² and Fons A.J. van de Loo², ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, The Netherlands, Nijmegen, Netherlands, ²Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands
Background/Purpose: The current treatment for patients with rheumatoid arthritis (RA) consists of biological drugs, often in combination with methotrexate. However, some patients fail to respond…
Abstract Number: 1920 • 2015 ACR/ARHP Annual Meeting
Differential Production of Th17-Related Cytokines By Toll like Receptor (TLR)-Ligands-Stimulated Monocyte-Derived Dendritic Cells (Mo-DCs) from Systemic Sclerosis (SSc) Patients; Relevance of IL-22 and IL-33 According to Disease Subtype and Stage
Tatiana Sofia Rodriguez-Reyna¹, Adrián Caballero¹, Luís Jiménez-Álvarez², Gustavo Ramirez², José Eduardo Márquez García², Alfredo Cruz Lagunas³, Guadualupe Lima⁴, Janette Furuzawa-Carballeda⁵, Luis Llorente¹ and Joaquin Zuniga⁶, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Immunology, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, ³Immunology, Instituto Nacional de Enfermedades Respiratorias, Mexico, Mexico, ⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, ⁶Immunology, Instituo Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, Mexico, Mexico
Background/Purpose: Systemic sclerosis (SSc) patients exhibit alterations in innate and acquired cellular responses including an enhanced inflammatory response to toll like receptor (TLR) agonists that…
Abstract Number: 1922 • 2015 ACR/ARHP Annual Meeting
Peripheral B Lymphocytes Secrete Both Interleukin 6 and Transforming Growth Factor-Beta and Potentiate Fibroblast Activation in Systemic Sclerosis
Nicolas Dumoitier^1,2,3,4, Sebastien Lofek^2,3,5, Alexis Regent⁶, Jonathan London⁷, Benjamin Chaigne^1,2,3,8, Benjamin Terrier^2,7,9,10, Nadine Varin-Blank^4,11 and Luc Mouthon^1,2,4,6, ¹Infection, Immunité, Inflammation, Institut Cochin, INSERM U1016, Paris, France, ²CNRS, UMR8104, Paris, France, ³Université Paris Descartes, Paris, France, ⁴Labex Inflamex, Université Sorbonne Paris Cité, Paris, France, ⁵Infection,Immunité, Inflammation, Institut Cochin, INSERM U1016, Paris, France, ⁶Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ⁷Internal Medecine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ⁸Internal Medecine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochinl, Paris, France, ⁹Infection, Immunité, Inflammation, Institut Cochin INSERM U1016, Paris, France, ¹⁰Université Paris Descartes, paris, France, ¹¹UFR SMBH, INSERM, UMR978, Bobigny, France
Background/Purpose: Systemic sclerosis (SSc) is a rare connective tissue disease characterized by fibroblasts activation, increased extra-cellular matrix synthesis associated with autoimmunity. However, the potential role…
Abstract Number: 2145 • 2015 ACR/ARHP Annual Meeting
Ixekizumab Improves Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis
Alice B. Gottlieb¹, Philip J. Mease², Raquel S. Cuchacovich^3,4, Catherine L. Shuler⁵, Chen-Yen Lin⁵, Russel T. Burge⁵, Suvajit Samanta⁵, Chin H. Lee⁵ and Dafna D. Gladman⁶, ¹Dermatology, Tufts Medical Center, Boston, MA, ²Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, WA, ³School of Medicine, Rheumatology Division, Indiana University, Indianapolis, IN, ⁴Bio Medicines Business Unit/Autoimmune Medical, Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease associated with psoriasis, peripheral arthritis, enthesitis, dactylitis, and spondylitis. PsA has a significant negative impact…
Abstract Number: 2876 • 2014 ACR/ARHP Annual Meeting
Interleukin-10 Receptor Blockade during Lcmv Infection Results in Macrophage Activation Syndrome-like Disease in Mice
Lehn K. Weaver¹ and Edward M. Behrens², ¹Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Pediatric Rheumatology, Childrens Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Macrophage activation syndrome (MAS) is the rheumatic disease-associated member of a group of hyperinflammatory syndromes characterized by uncontrolled cytokine storm manifest as unremitting fevers,…
Abstract Number: 947 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of NNC01140006, an Anti-IL-21 Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis
Juan D. Cañete¹, Piotr Leszczynski², Rikke Riisbro³ and Klaus S. Frederiksen³, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Department of Rheumatology and Rehabilitation, Poznan Medical University, Poznan, Poland, ³Novo Nordisk A/S, Søborg, Denmark
Background/Purpose A phase 2, randomised, double-blind, placebo-controlled, parallel-group trial was conducted to evaluate the efficacy and safety of NNC0114-0006 in patients with active rheumatoid arthritis…
Abstract Number: 2879 • 2014 ACR/ARHP Annual Meeting
Epigallocatechin-3-Gallate (EGCG) Suppresses IL-1β-Induced IL-6 and IL-8 Synthesis By Selectively Inhibiting TAK1 Activation in Human Rheumatoid Arthritis Synovial Fibroblasts
Anil Singh¹, Sharayah Riegsecker², Sadiq Umar¹ and Salahuddin Ahmed¹, ¹Department of Pharmaceutical Sciences, Washington State University, Spokane, WA, ²Department of Pharmacology, University of Toledo, Toledo, OH
Background/Purpose: In rheumatoid arthritis (RA), the role of interleukin-1β (IL-1β) signaling proteins (IRAK-1/TAK-1/TRAF-6) proximal to IL-1 receptor in mediating proinflammatory response is not completely understood.…
Abstract Number: 665 • 2014 ACR/ARHP Annual Meeting
Safety and Efficiency of Low-Dose Interleukin-2 Treatment in Systemic Lupus Erythematosus
Jing He¹, Xia Zhang², Xiaolin Sun³, Jianping Guo³, Yunbo Wei⁴, Zhaohua Hou⁴, Yu Di⁵ and Zhanguo Li³, ¹Department of Rheumatology & Immunology, Peking University People's Hospital, Beijing, China, ²Department of Rheumatology & immunology, Peking University People's Hospital, Beijing, China, ³Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ⁴Immunology for Environment and Health, Shandong Analysis and Test Center, Shandong Academy of Science, Shandong, China, ⁵Molecular Immunomodulation Laboratory, Monash University, Clayton, Austria
Background/Purpose Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by loss of tolerance to nuclear self-antigens, production of pathogenic autoantibodies and damage tomultiple organs.…
Abstract Number: 2837 • 2014 ACR/ARHP Annual Meeting
Induction of Clinical Remission By Low-Dose Interleukin-2 in Refractory SLE
Jens Y. Humrich¹, Caroline von Spee-Mayer¹, Elise Siegert¹, Angelika Rose¹, Tobias Alexander², Falk Hiepe¹, Andreas Radbruch³, Gerd Burmester⁴ and Gabriela Riemekasten¹, ¹Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany, ³German Rheumatism Research Centre Berlin (DRFZ), an institute of the Leibniz Association, Berlin, Germany, ⁴Charité University Medicine, Dept. Medicine/Rheumatology and Clinical Immunology, Berlin, Germany
Background/Purpose Interleukin-2 (IL-2) is crucial for the growth and survival of regulatory T cells (Treg), and thus for the control of autoimmunity. In previous studies…
Abstract Number: 322 • 2014 ACR/ARHP Annual Meeting
Superior Therapeutic Efficacy of a Novel Oral Small Molecule Retinoic Acid Receptor-Related Orphan Receptor Gamma T [Rorgt] Inverse Agonist Inv-17: A Promising Safe & Efficacious Treatment for Rheumatoid Arthritis
Anderson Gaweco^1,2, Samantha Palmer¹, Rambon Shamilov¹, Caroline Stremnitzer¹, Katie Matthews¹, Michael Fisher¹, William Windsor¹, James Blinn¹, Ellen M. Ginzler³ and Jefferson Tilley¹, ¹Innovimmune Biotherapeutics, Brooklyn, NY, ²SUNY-Downstate Medical Center, Brooklyn, NY, ³Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY
Background/Purpose: T helper 17 [TH17] cells and its production of TH17 cytokines IL-17A and IL-17F play a critical role in the pathogenesis of RA and…
Abstract Number: 2168 • 2014 ACR/ARHP Annual Meeting
Extramedullary Myelopoiesis Drives Persistent Toll-like Receptor-Mediated Inflammation
Lehn K. Weaver¹ and Edward M. Behrens², ¹Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Pediatric Rheumatology, Childrens Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Many rheumatic diseases are driven by chronic, repeated activation of Toll-like receptors (TLR) causing the initiation and perpetuation of disease. However, TLR-activated innate immune…
Abstract Number: 311 • 2014 ACR/ARHP Annual Meeting
Inhibition of Natural Killer (NK) Cell Cytotoxicity By Interleukin-6 (IL-6): Implications for the Pathogenesis of Macrophage Activation Syndrome
Loredana Cifaldi¹, Giusi Prencipe², Ivan Caiello², Claudia Bracaglia², Raffaele Strippoli³ and Fabrizio De Benedetti Sr.², ¹Paediatric Haematology/Oncology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, ²Department of Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, ³Cellular Biotechnologies and Haematology, Sapienza Rome University, Rome, Italy
Background/Purpose: MAS occurs frequently in patients with active systemic juvenile idiopathic arthritis(s-JIA) and because of the similarities with Haemophagocytic Lymphohistiocytosis (HLH) is classified among secondary…
Abstract Number: 2039 • 2014 ACR/ARHP Annual Meeting
Among Persons Assayed with Lower Serum Interleukin-1 Beta (IL-1β) Levels, Serum Androstenedione (Δ4A) and Testosterone (T) Were Significantly Lower in a Community-Based Cohort of Rheumatoid Arthritis Multi-Years before Clinical Onset (Pre-RA) Than in Non-RA Matched Control (CN) Subjects
Alfonse T. Masi, Azeem A. Rehman and Jean C. Aldag, Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL
Background/Purpose: Dysregulations in androgenic-anabolic (A-A) steroids and cytokines are recognized in RA and pre-RA subjects (Rheum Dis Clin N Am 2005; 31: 131-60). However, deviations…
Abstract Number: 81 • 2014 ACR/ARHP Annual Meeting
Elevated Peripheral Blood Leukocyte Inflammatory Gene Expression in Radiographic Progressors with Symptomatic Knee Osteoarthritis: NYU and OAI Cohorts
Mukundan Attur¹, Alexander Statnikov², Svetlana Krasnokutsky Samuels¹, Virginia B. Kraus³, Joanne Jordan⁴, Braxton D. Mitchell⁵, Michelle Yau⁶, Jyoti Patel¹, Constantin F. Aliferis², Marc C. Hochberg⁷, Jonathan Samuels¹ and Steven B. Abramson⁸, ¹Rheumatology, NYU Langone Medical Center, New York, NY, ²Center for Health Informatics and Bioinformatics, NYU Langone Medical Center, New York, NY, ³Medicine/Rheumatology, Duke University Medical Center, Durham, NC, ⁴Thurston Arthritis Research Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵Departments of Medicine and Epidemiology & Public Health, University of Maryland School of Medicine, Baltimore, MD, ⁶Epidemiology and Public Health, University of Maryland, Baltimore,, MD, ⁷Medicine, University of Maryland School of Medicine, Baltimore, MD, ⁸Dept of Rheumatology/Medicine, NYU Langone Medical Center, New York, NY
Background/Purpose: We and others have demonstrated low grade inflammation exists in OA joint tissues, where it may contribute to disease pathogenesis. In the current studies…

« Previous Page
1
…
5
6
7
8
9
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].